Vista Capital Partners Inc. bought a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,716 shares of the company’s stock, valued at approximately $972,000.
A number of other large investors also recently made changes to their positions in ABBV. Financial Freedom LLC acquired a new stake in shares of AbbVie during the third quarter worth approximately $29,000. Burk Holdings LLC purchased a new position in AbbVie during the second quarter valued at approximately $30,000. Marquette Asset Management LLC grew its position in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. IMG Wealth Management Inc. increased its stake in AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the period. Finally, Principia Wealth Advisory LLC increased its stake in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.
AbbVie Price Performance
Shares of AbbVie stock opened at $295.18 on Monday. The firm has a market cap of $521.77 billion, a price-to-earnings ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20. The stock has a 50-day simple moving average of $275.51 and a 200-day simple moving average of $240.91. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the prior year, the company posted $1.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a $1.82 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is presently 119.10%.
Insider Buying and Selling
In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on ABBV shares. Rothschild & Co Redburn increased their target price on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. BMO Capital Markets set a $315.00 price target on shares of AbbVie in a report on Wednesday, November 4th. Piper Sandler boosted their price target on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Barclays upped their price target on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 21st. Finally, Cantor Fitzgerald increased their price objective on AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $297.46.
View Our Latest Stock Report on ABBV
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Recommended Stories
- Five stocks we like better than AbbVie
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
